Uncover key drivers, emerging technologies, and competitive movements shaping the neuromuscular disorders market from 2026–2035 with trusted insights from The Business Research Company
What was the valuation of the Neuromuscular Disorders Market in 2026, and what figure is it projected to hit by 2030?
The neuromuscular disorders market has seen robust expansion over recent years. It is anticipated to increase from $8.31 billion in 2025 to $8.98 billion in 2026, progressing at a compound annual growth rate (CAGR) of 8.0%. This historical growth can be attributed to several factors, including the increasing prevalence of genetic neuromuscular conditions, greater awareness leading to earlier diagnosis and treatment options, a growing demand for effective therapies for rare disorders, increasing research initiatives in conditions like muscular dystrophy and ALS, and the rising adoption of advanced diagnostic technologies.
The neuromuscular disorders market size is anticipated to undergo significant expansion over the coming years. It is projected to achieve a valuation of $12.07 billion in 2030, driven by a compound annual growth rate (CAGR) of 7.7%. This growth during the forecast period is attributable to increasing patient advocacy and support group activities, the growing demand for biologics and gene therapies, enhanced recognition of neuromuscular disorders in pediatric contexts, a rise in government initiatives for managing rare diseases, and a heightened focus on home-based care and rehabilitation services. Prominent trends for the forecast period include advancements in gene-editing technologies for targeted therapies, innovations in RNA-based treatment platforms, the integration of AI for more rapid neuromuscular diagnosis, progress in stem-cell-based regenerative treatments, and breakthroughs in wearable devices for continuous patient monitoring.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=30678&type=smp
Which Drivers Are Affecting Market Participation In The Neuromuscular Disorders Market?
The anticipated expansion of the neuromuscular disorders market is linked to the increasing need for personalized medicine. This medical strategy focuses on customizing therapies for each patient, considering their genetic makeup, environmental influences, and lifestyle choices to enhance treatment efficacy and patient care. Advances in genomic technologies, which facilitate precise identification of genetic variations and the creation of bespoke treatments, are fueling the growing demand for personalized medicine. It significantly improves the management of neuromuscular disorders by adapting treatments according to unique genetic, molecular, and physiological profiles of patients, leading to better patient outcomes through targeted interventions, maximized effectiveness, and reduced side effects. A notable example is provided by the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, stating that in February 2024, the U.S. Food and Drug Administration (FDA) gave its approval to 26 new personalized medicines in 2023, which marks a substantial rise from the 12 approved in 2022. Consequently, the heightened demand for personalized medicine is serving as a primary catalyst for the expansion of the neuromuscular disorders market.
What Segment Categories Are Covered In The Neuromuscular Disorders Market?
The neuromuscular disorders market covered in this report is segmented –
1) By Disease Type: Spinal Muscular Atrophy (SMA), Amyotrophic Lateral Sclerosis (ALS), Duchenne Muscular Dystrophy (DMD), Myasthenia Gravis, Other Muscular Dystrophies
2) By Product Type: Pharmaceuticals, Biologics, Diagnostic Tools, Assistive Devices
3) By Route of Administration: Oral, Injectable, Other Route of Administrations
4) By Treatment: Gene Therapy, Drug Therapy, RNA-Based Therapy, Enzyme Replacement Therapy, Physical Therapy And Rehabilitation, Respiratory Care
Subsegments:
1) By Spinal Muscular Atrophy: SMA Type 1, SMA Type 2, SMA Type 3, SMA Type 4, SMA with Respiratory Distress (SMARD)
2) By Amyotrophic Lateral Sclerosis: Sporadic ALS, Familial ALS, Limb-Onset ALS, Bulbar-Onset ALS, Respiratory-Onset ALS
3) By Duchenne Muscular Dystrophy: Early-Onset DMD, Late-Onset DMD, Exon Deletion Mutations, Exon Duplication Mutations, Point Mutations
4) By Myasthenia Gravis: Generalized Myasthenia Gravis, Ocular Myasthenia Gravis, Seropositive MG, MuSK-Positive MG, Seronegative MG
5) By Other Muscular Dystrophies: Becker Muscular Dystrophy (BMD), Limb-Girdle Muscular Dystrophy (LGMD), Facioscapulohumeral Muscular Dystrophy (FSHD), Congenital Muscular Dystrophies, Myotonic Dystrophy
How Are New Market Trends Shaping The Landscape Of The Neuromuscular Disorders Market?
Major companies operating in the neuromuscular disorders market are focusing on developing advanced treatments, such as gene replacement therapies, to address the underlying genetic causes of conditions like Duchenne muscular dystrophy and spinal muscular atrophy. Gene replacement therapy involves engineered biological products that deliver functional copies of defective genes to restore or improve muscle function in patients with inherited neuromuscular conditions, offering a potential one-time treatment that reduces the need for long-term chronic therapy. For instance, in November 2025, Novartis, a Switzerland-based pharmaceuticals company, received the US Food and Drug Administration (FDA) approval for Itvisma (onasemnogeneabeparvovec-brve), representing the first and only gene replacement therapy for the treatment of children two years of age and older, teens, and adults with spinal muscular atrophy (SMA) who have a confirmed mutation in the survival motor neurone 1 (SMN1) gene. This therapy is specifically designed to treat the genetic underlying cause of SMA with a single, fixed dosage that does not require body weight or age adjustments. Itvisma can enhance motor function by substituting the SMN1 gene, which may lessen the requirement for long-term medication used in conjunction with other current treatments for this population.
Which Key Market Players Are Investing In Expansion And Innovation Within The Neuromuscular Disorders Market?
Major companies operating in the neuromuscular disorders market are AbbVie Inc., Novartis AG, Takeda Pharmaceutical Company Limited, The Trustees of the University of Pennsylvania, Biogen Inc., Sarepta Therapeutics Inc., argenx SE, PTC Therapeutics Inc., Catalyst Pharmaceuticals Inc., Mayo Clinic Laboratories, Fulgent Genetics Inc., Dyne Therapeutics Inc., The Regents of the University of California, GeneDx LLC, PepGen Inc., Centogene N.V., Scholar Rock Holding Corporation, Solid Biosciences Inc., Vita Therapeutics Inc., NMD Pharma A/S, Cytokinetics Incorporated, Sudo Biosciences Inc.
Access The Complete Report For Deeper Market Insights:
https://www.thebusinessresearchcompany.com/report/neuromuscular-disorders-market-report
Which Regions Are Poised For Strategic Growth In The Neuromuscular Disorders Market?
North America was the largest region in the neuromuscular disorders market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuromuscular disorders market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Neuromuscular Disorders Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=30678&type=smp
Browse Through More Reports Similar to the Global Neuromuscular Disorders Market 2026, By The Business Research Company
Muscle Spasticity Market Report 2026
https://www.thebusinessresearchcompany.com/report/muscle-spasticity-global-market-report
Muscle Wasting Disorders Market Report 2026
https://www.thebusinessresearchcompany.com/report/muscle-wasting-disorders-global-market-report
neurological disorder drugs global market report
https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model